This article examines how bioprinting improves cancer models, overcoming traditional limits and advancing current therapies.
ATCC and the Broad Institute report the development of engineered isogenic cancer models designed to replicate resistance to targeted therapies, beginning with osimertinib, the latest-generation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results